The global Epigenetics Market size is expected to reach USD 22.05 billion by 2025, according to a new study by Grand View Research, Inc., progressing at a CAGR of 19.7% during the forecast period. The growing prevalence of cancer and other diseases worldwide with an epigenetic modification base is expected to drive the market during the forecast period.
Diagnostic
companies are coming up with new products such as antibodies specific for the
detection of modifications and new upgraded kits for easy and efficient
detection of biomarkers. This is estimated to attract pharmaceutical companies
to collaborate for the development of therapeutic drugs, which will work in
favor of the market.
The
presence of pipeline drugs and their expected commercialization is anticipated
to boost the growth of the market. For instance, Ramucirumab (Cyramza) by Eli
Lilly and Company was approved by the FDA for use in combination with Folfiri
for the treatment of patients with metastatic colorectal cancer.
Technology
advancements in the epigenetics industry are majorly focusing on the detection
of methylation markers related to cancer development. For instance, Epi proLung
BL Reflex Assay by Epigenomics helps in the diagnosis of lung cancer by
determining methylation of SHOX2 biomarker gene.
Related Press Release@ Epigenetics
Market Report
Epigenetics Market Report Highlights:
- On the basis
of product, reagents held the largest share in the market in 2017. They
are projected to amount to approximately USD 7.06 billion by 2025 owing to
increasing R&D activities in the field of epigenetics
- The kits
segment is expected to post a CAGR of over 20.0% due to the need for rapid
and accurate detection techniques
- DNA
methylation, on the basis of technology, held the leading revenue share in
the market in 2017, accounting for just over 47.0%. The rapid adoption of
advanced techniques such as methylation-sensitive PCR (MSP) to improve
diagnostics efficiency is poised to bolster the growth of the segment
- North
America commanded the leading position in the global arena with a share of
40.0% in 2017. The growth of the regional market can be attributed to the
increasing prevalence of cancer and growing collaborations between large
pharmaceutical firms for the development of improved therapeutics
- Asia Pacific
is estimated to register a noteworthy CAGR of 22.1% during the forecast
period owing to the presence of a large target population coupled with
high unmet clinical needs
- Some of the
major players of epigenetics market are
Illumina; Abcam; Diagenode; Thermo Fisher Scientific; Merck; Zymo
research; Qiagen; CellCentric Ltd; Chroma Therapeutics Ltd; Eisai Co. Ltd;
Novartis International AG; Oncolys Biopharma Inc.; Syndax Pharmaceuticals,
Inc.; Valirx Plc; and Sigma-Aldrich Corporation
- Extensive
R&D initiatives for the development of novel drugs and the presence of
strong product pipeline are expected to further boost market growth over
the forecast period.
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com
No comments:
Post a Comment